Mastodon Feed: Post

Mastodon Feed

Boosted by jsonstein@masto.deoan.org ("Jeff Sonstein"):
ml@social.mitexleo.one ("Mitex Leo") wrote:

Fifteen years ago, Bangladesh relied on costly imported cancer drugs, spending over Tk1,000 crore annually and leaving treatment out of reach for most. Over the past decade, local pharmaceutical growth, spurred by rising cancer cases and supportive policies, has transformed access - now, about 95% of cancer medicines are made domestically, making life-saving care far more affordable.

Report: https://www.tbsnews.net/bangladesh/health/tk60000-tk4000-how-local-pharma-makes-cancer-drugs-affordable-1279776

#news #healthcare #medicine #bangladesh #us #drug #cancer

Infographic titled “Bangladesh’s Cancer Drug Revolution: At a Glance” by TBS Insights and IPDC Finance. It explains how Bangladesh shifted from importing costly cancer medicines to producing about 95% locally. Key points: 15 years ago, over Tk1,000 crore was spent on imports; now 17–18 firms manufacture oncology drugs. Government support includes VAT exemption, duty waivers on raw materials and machinery, and reduced withholding tax (from 5% to 2%). A section on price drop and sales shows steep cost reductions: Erlotinib – import Tk7,500, local Tk750 Pegfilgrastim – import Tk40,000, local Tk4,000–Tk20,000 Filgrastim – import Tk60,000, local Tk4,000 Local production cut prices up to 10–12 times, with monthly oncology drug sales of Tk50–55 crore. Leading manufacturers: Beacon, Incepta, Renata, One Pharma, and ACI Pharma. According to WHO data, Bangladesh records 167,256 new cancer cases and 116,598 deaths each year. The infographic uses icons for money, lab equipment, medical bottles, and a pink cancer ribbon.